Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec 7;103(12):1858-69.
doi: 10.1038/sj.bjc.6605984. Epub 2010 Nov 9.

Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review

T Lampejo  1 , D Kavanagh, J Clark, R Goldin, M Osborn, P Ziprin, S Cleator
Affiliations

Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review

T Lampejo et al. Br J Cancer. .

Abstract

Background: recent decades have seen combination chemoradiotherapy become the standard treatment for anal squamous cell carcinoma (SCC). However, the burden of this disease continues to rise, with only 10% of patients with metastatic disease surviving >2 years. Further insight into tumour characteristics and molecular biology may identify novel therapeutic targets. This systematic review examines current prognostic markers in SCC of the anus.

Methods: an extensive literature search was performed to identify studies reporting on biomarkers in anal cancer in the context of clinical outcome following treatment primarily with chemoradiotherapy.

Results: in all, 21 studies were included. A total of 29 biomarkers were studied belonging to 9 different functional classes. Of these biomarkers, 13 were found to have an association with outcome in at least one study. The tumour-suppressor genes p53 and p21 were the only markers shown to be of prognostic value in more than one study.

Conclusions: an array of biomarkers have been identified that correlate with survival following chemoradiotherapy in anal cancer. However, investigators are yet to identify a biomarker that has the ability to consistently predict outcome in this disease. Further studies are needed to elucidate whether these candidate biomarkers demonstrate their optimum value when they serve as targets for new therapeutic strategies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram representing the selection process for the studies included in the final analysis.
Figure 2
Figure 2
The classes and subclasses of biomarkers evaluated in the final 21 studies (highlighted in bold are the biomarkers that were associated with outcome in at least one study).
See this image and copyright information in PMC

References

    1. Abbott DE, Margaryan NV, Jeruss JS, Khan S, Kaklamani V, Winchester D, Hansen N, Rademaker A, Khalkhali-Ellis Z, Hendrix MJ (2010) Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology. Cancer Biol Ther 9(1): 23–30 - PMC - PubMed
    1. Ajani JA, Wang X, Izzo JG, Crane CH, Eng C, Skibber JM, Das P, Rashid A (2009) Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci 55: 1098–1105 - PubMed
    1. Allal AS, Alonso-Pentzke L, Remadi S (1998) Apparent lack of prognostic value of MIB-1 index in anal carcinomas treated by radiotherapy. Br J Cancer 77(8): 1333–1336 - PMC - PubMed
    1. Allal AS, Gervaz P, Brundler MA (2004) Cyclin D1, cyclin E, and p21 have no apparent prognostic value in anal carcinomas treated by radiotherapy with or without chemotherapy. Br J Cancer 91(7): 1239–1244 - PMC - PubMed
    1. Allal AS, Waelchli L, Brundler MA (2003) Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma. Clin Cancer Res 9(17): 6489–6496 - PubMed

Publication types

MeSH terms

Substances